Natural Product (NP) Details
| General Information of the NP (ID: NP6934) | |||||
|---|---|---|---|---|---|
| Name |
Chlorogenic acid
|
||||
| Synonyms |
CHLOROGENIC ACID; 327-97-9; 3-Caffeoylquinic acid; 3-O-Caffeoylquinic acid; 3-(3,4-Dihydroxycinnamoyl)quinic acid; Chlorogenate; Heriguard; Hlorogenic acid; Caffeoyl quinic acid; NSC-407296; 3-Caffeoylquinate; UNII-318ADP12RI; 5-O-(3,4-Dihydroxycinnamoyl)-L-quinic acid; CCRIS 1400; Chlorogenic acid (8CI); EINECS 206-325-6; NSC 70861; NSC 407296; 3-trans-Caffeoylquinic acid; CHEMBL284616; 318ADP12RI; CHEBI:16112; 1,3,4,5-tetrahydroxycyclohexanecarboxylic acid 3-(3,4-dihydroxycinnamate); 3-(3,4-Dihydroxycinnamoyl)quinate
Click to Show/Hide
|
||||
| Species Origin | Imperata cylindrica ... | Click to Show/Hide | |||
| Imperata cylindrica | |||||
| Prunus mume | |||||
| Vachellia nilotica | |||||
| Disease | Ulcerative colitis [ICD-11: DD71] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C16H18O9
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)O
|
||||
| InChI |
1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(20)25-12-7-16(24,15(22)23)6-11(19)14(12)21/h1-5,11-12,14,17-19,21,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14-,16+/m1/s1
|
||||
| InChIKey |
CWVRJTMFETXNAD-JUHZACGLSA-N
|
||||
| CAS Number |
CAS 202650-88-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Regorafenib | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Co-treatment with Regorafenib and CGA enhanced Regorafenib action, reducing its cytotoxicity in HCC cells. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | ERK2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Hep 3B2.1-7 | CVCL_0326 | Childhood hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Methotrexate | Leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | COX-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | GPT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | LDHA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Attennuation | Pro-inflammatory and apoptotic mediators | ||||
| Improvement | Antioxidant competence | |||||
| In-vivo Model | 6-8 weeks old Male Wistar rats (150-200 g) were use in this study. | |||||
| Experimental
Result(s) |
CGA has perfective effect against MTX-induced liver injury. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Glucose-6-phosphate translocase (SLC37A4) | Molecule Info | [5] | |
| KEGG Pathway | Carbohydrate digestion and absorption | Click to Show/Hide | ||
| Pathwhiz Pathway | Gluconeogenesis | Click to Show/Hide | ||
| 2 | Mitochondrial Electron Transport Chain | |||
| Reactome | Glucose transport | Click to Show/Hide | ||
| WikiPathways | Metabolism of carbohydrates | Click to Show/Hide | ||
| 2 | Hexose transport | |||
